Dr. Lenz Discusses Immunotherapy in Gastrointestinal Cancers

Heinz-Josef Lenz, MD, FACP
Published: Saturday, Jul 01, 2017



Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal (GI) cancers.

Immunotherapy will become part of the treatment armamentarium in GI cancer, particularly colorectal cancer, says Lenz.

A US clinical trial indicated that Immunoscore is prognostically significant. It validated the presence of CD3 and CD8 cells in the tumor and in the invasive margin.
 


Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal (GI) cancers.

Immunotherapy will become part of the treatment armamentarium in GI cancer, particularly colorectal cancer, says Lenz.

A US clinical trial indicated that Immunoscore is prognostically significant. It validated the presence of CD3 and CD8 cells in the tumor and in the invasive margin.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x